SLC5A2 and diabetic kidney disease: In particular, the SGLT2 inhibitor empagliflozin has been reported to alleviate T2DM-related DKD by reducing LPS-producing bacteria and increasing SCFA-producing bacteria in DKD mice (Deng et al.